Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Biotechnology

Healthcare
$0.90 +3.01%

+$0.06 today

Market cap
$54.28M
Beta
1.19
P/E (TTM)
-4.2
EPS (TTM)
-$0.45
52W Low $1.07High $6.18

Volume 1.45M

Average 2.13M

ALDX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Aldeyra Therapeutics, Inc.NASDAQ: ALDX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation turns negative

Q1 FY2026 stock-based compensation was -$987.55K, compared with $2.22M a year earlier. Trailing-twelve-month stock-based compensation was $2.88M. Over 3 fiscal years it compounded at -9.8% a year.

Context

  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly stock-based compensation holds near -$987.55K or moves back toward the trailing-twelve-month quarterly average of $719.96K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$987.55K-190.6% QoQ
Last fiscal yearDec 2025
$6.09M-23.6% YoY
LTMMar 2026
$2.88M-66.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-144.4%——
1 year-23.6%——
3-year CAGR-9.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
6.09M USD
Year-over-year change
-23.6%
4-year CAGR
-3.8%

Stock-Based Compensation vs competitors

How ALDX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -66.7% is the 9th highest of 10, against a peer median of -5.4%.
  • Over three fiscal years its annual growth of -9.8% compares with a peer median of +34.5%.
ALDX Competitors
Stock-Based Compensation for ALDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SLNSilence Therapeutics plcLTM Mar 2026$14.34M USD—-14.0%1556.3%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$11.29M USD+31.2%+73.3%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$11.09M USD+34.6%+121.4%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$7.02M USD-5.4%+66.3%—
MREOMereo BioPharma Group plcLTM Mar 2026$6.93M USD-9.1%+16.8%1385.0%
GNLXGenelux CorporationLTM Mar 2026$5.84M USD+8.8%+34.5%72950.0%
CADLCandel Therapeutics, Inc.LTM Mar 2026$4.96M USD+8.1%+18.3%—
AMRNAmarin Corporation plcLTM Mar 2026$3.95M USD-191.3%—1.8%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$2.88M USD-66.7%-9.8%—
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
CLLSCellectis S.A.LTM Mar 2026$1.28M USD-60.6%—1.9%
Peer median (excluding ALDX) —-5.4%+34.5%730.0%

Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(57.78M)(62.02M)(37.54M)(55.85M)(33.85M)
Depreciation & Amortization264.18K258.71K262.78K249.62K251.99K
Deferred Income Tax00000
Stock-Based Compensation7.11M8.29M5.75M7.97M6.09M
Change in Working Capital7.44M(3.44M)861.18K5.91M(5.18M)
Accounts Receivables00000
Inventory00000
Accounts Payables638.06K(886.08K)1.2M(1.16M)(21.99K)
Other Working Capital6.8M(2.56M)(343.25K)7.07M(5.16M)
Other Non-Cash Items409.47K283.91K339.65K(1.49M)(664.43K)
Operating Cash Flow(42.56M)(56.64M)(30.33M)(43.21M)(33.35M)
Capital Expenditures(7.81K)(16.32K)000
Acquisitions (Net)016.32K000
Purchases of Investments0(92.94M)0(96.92M)(40.26M)
Sales of Investments063M30M52M88M
Other Investing Activities0(16.32K)000
Investing Cash Flow(7.81K)(29.95M)30M(44.92M)47.74M
Debt Repayment00(1.04M)(292.5K)0
Common Stock Issued189.81M1.22M305.23K121.08K1.12M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities4.68M0(532.95K)0(444)
Financing Cash Flow194.5M1.22M(1.27M)(171.42K)1.12M
Effect of Forex Changes00000
Net Change in Cash151.93M(85.37M)(1.6M)(88.3M)15.51M
Free Cash Flow(42.56M)(56.65M)(30.33M)(43.21M)(33.35M)

Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.